GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » 3-Year EPS without NRI Growth Rate

Elicera Therapeutics AB (OSTO:ELIC) 3-Year EPS without NRI Growth Rate : -76.10% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB 3-Year EPS without NRI Growth Rate?

Elicera Therapeutics AB's EPS without NRI for the three months ended in Dec. 2023 was kr-0.24.

During the past 3 years, the average EPS without NRI Growth Rate was -76.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of Elicera Therapeutics AB was -76.10% per year. The lowest was -361.00% per year. And the median was -218.55% per year.


Competitive Comparison of Elicera Therapeutics AB's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Elicera Therapeutics AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicera Therapeutics AB's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's 3-Year EPS without NRI Growth Rate falls into.



Elicera Therapeutics AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Elicera Therapeutics AB  (OSTO:ELIC) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Elicera Therapeutics AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry
Traded in Other Exchanges
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines